EPO Scathed But Survives ODAC Challenge; Cmte. Calls For Additional Trials

Sponsors of erythropoiesis-stimulating agents should conduct additional safety studies to support continued marketing in the oncology setting, FDA's Oncologic Drugs Advisory Committee unanimously recommends